Back to today’s briefing

Story perspectives

McDonald's Adapts Menu for GLP-1 Users Amid Sales Surge

2/13/2026

23 5 Full Breakdown

Summary

Story summary

McDonald's is adapting its menu to GLP-1 weight-loss drug users, such as Ozempic and Wegovy.
During an earnings call, Chris Kempczinski, McDonald's Chief Executive Officer, said the company is testing high-protein items, including options similar to Shake Shack.
The company reported a 5.7% rise in global sales, driven by its $5 meal deal.
McDonald's plans to open 2,200 restaurants.
The rise in GLP-1 adoption is reshaping fast-food consumer behavior.

1 of 1

Story summary

McDonald's is adapting its menu to GLP-1 weight-loss drug users, such as Ozempic and Wegovy.
During an earnings call, Chris Kempczinski, McDonald's Chief Executive Officer, said the company is testing high-protein items, including options similar to Shake Shack.
The company reported a 5.7% rise in global sales, driven by its $5 meal deal.
McDonald's plans to open 2,200 restaurants.
The rise in GLP-1 adoption is reshaping fast-food consumer behavior.